Polypyridylruthenium(II) complexes exert anti-schistosome activity and inhibit parasite acetylcholinesterases

BACKGROUND: Schistosomiasis affects over 200 million people and there are concerns whether the current chemotherapeutic control strategy (periodic mass drug administration with praziquantel (PZQ)—the only licenced anti-schistosome compound) is sustainable, necessitating the development of new drugs....

Descripción completa

Detalles Bibliográficos
Autores principales: Sundaraneedi, Madhu K., Tedla, Bemnet A., Eichenberger, Ramon M., Becker, Luke, Pickering, Darren, Smout, Michael J., Rajan, Siji, Wangchuk, Phurpa, Keene, F. Richard, Loukas, Alex, Collins, J. Grant, Pearson, Mark S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746282/
https://www.ncbi.nlm.nih.gov/pubmed/29240773
http://dx.doi.org/10.1371/journal.pntd.0006134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746282/
https://www.ncbi.nlm.nih.gov/pubmed/29240773
http://dx.doi.org/10.1371/journal.pntd.0006134

Ejemplares similares